Madia Lozupone, MD, PhD is an expert in Neurology at University of Bari Aldo Moro (Italy). As of October 2026, ScienceLeadR ranks Madia Lozupone in the top 1% of experts worldwide for Neurocognitive Disorders. Madia Lozupone has authored 199 publications, the most recent in 2026. SLR score: 609 (community average: 125). How the SLR is computed.

LeadR Profile

Madia Lozupone, MD, PhD University of Bari Aldo Moro Italy
609 ScienceLeadR Reputation 609
Network Map

Neurology

Subspecialties: Geriatrics - Pharmacy - Biochemistry

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Short Biography

Dr. Madia Lozupone is a clinical researcher at the Psychiatric Unit, Department of Mental Health, ASL Bari, Italy. Since 2012, immediately after completing her psychiatric training, she has been involved in the PRIN2009E4RM4Z project (the GreatAGE Study), a population-based study on aging conducted in South-East Italy. In October 2017, she obtained her PhD in Neurosciences and Translational Medicine at the University of Bari Aldo Moro, Italy, with a thesis entitled “Late-Life Depression: The Contribution of Population-Based Studies. Assessment Methodologies, Prevalence, and Determinants.” Her primary research interest lies in the epidemiology of old-age psychiatry. Within the GreatAGE Study—“Impact of Central and Peripheral Auditory Dysfunctions on the Risk of Onset of Subjective Cognitive Impairment, Mild Cognitive Impairment, Dementia, Alzheimer’s Disease, Vascular Dementia, and Late-Onset Depression”—Dr. Lozupone has focused on the psychiatric assessment component, investigating determinants, correlates, and treatment adherence in common psychiatric disorders in older adults, particularly late-life depression. The project involves the Neurology, Geriatrics, Otolaryngology, and Psychiatry Units of the University of Bari Aldo Moro and is conducted at the Laboratory of Epidemiology and Biostatistics of the IRCCS “S. De Bellis.” Her research activity has primarily centered on depressive disorders in older adults (≥65 years), with additional studies on anxiety disorders, psychosis, and adjustment disorders. Since 2015, Dr. Lozupone has been actively involved in the European Psychiatric Association (EPA) Congress. Her contributions include: 2014: Free oral communication — “The GreatAGE Study: Prevalence of Late-Onset Depression in an Elderly Rural Community of Castellana Grotte (Italy)” 2015: E-poster oral presentation — “Prevalence of Anxiety Disorders and Comorbid Affective Disorders in the Elderly of Castellana Grotte (Italy)” 2016: Free oral communication — “Validity of the Geriatric Depression Scale-30 Against the Gold Standard Diagnosis of Depression in Older Age: The GreatAGE Study” At EPA 2017, she presented additional data on swallowing disorders in elderly patients with psychiatric conditions and on variables influencing depression diagnosis in older adults. At EPA 2019, she presented two studies on suicidal ideation in older adults and the association between hearing impairment and late-life depression. In EPA 2022, she presented research on suicide risk factors in older age. She is currently collaborating with Professor Brett Thombs (McGill University, Canada) and the DEPRESSD Project Steering Committee on a meta-analysis examining the diagnostic accuracy of the Geriatric Depression Scale (GDS) for detecting major depression. Since 2015, another key research interest has been pharmacogenetics, particularly the study of genetic polymorphisms, adverse drug reactions, and personalized treatment strategies in “revolving door” psychiatric patients, with specific focus on Cytochrome P450 2D6.

Organizations

Career arc: 2013 - 2026

Source: PubMed

Azienda Sanitaria Locale Bari

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 199

Citations

Citations: 5 827 1st author: 40 Last author: 20 Unique author: 1


Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Anti-amyloid drugs: Integrated clinical pathways for treating older patients with frailty and dementia.
PMID 42641765 — dementia, pharmaceutical preparations, aging, therapeutics, amyloid, frailty
Ageing Res Rev20260
Correction: Zupo et al. Dietary Intake of Polyphenols and All-Cause Mortality: A Systematic Review with Meta-Analysis. Metabolites 2024, 14, 404.
PMID 42646339 — mortality, polyphenols
Metabolites20260
Editorial: Tracing loneliness in aging: understanding the interplay and exploring innovative interventions.
PMID 42597382 — loneliness, depression, social isolation, aging, frailty
Front Psychiatry20260
Do sigma-1 receptor agonists offer therapeutic promise for Alzheimer's disease?
PMID 42459149 — alzheimer disease, drug therapy, biomarkers, therapeutics
Expert Opin Pharmacother20260
Clinically Assessed Tooth Loss and Malnutrition Risk in U.S. Older Adults.
PMID 42457541 — tooth, malnutrition, tooth loss, dentures, dental materials, frailty
J Oral Rehabil20261

LeadR Networks

Main global connection map